Back

The influence of endothelial dysfunction and the prognosis in patients with myocardial infarction with non-obstructive coronary arteries.

30 August 2025 (09:05 - 09:15)
Organised by: Logo
Congress Presentation Part of: Non-obstructive coronary disease: what's new in assessment and management Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Hisaya Kondo

Yokohama City University Medical Center, Yokohama (Japan)

5 More presentations in this session

Presentation thumbnail
How late is too late? Influence of CMR timing in suspected MINOCA
Doctor G. Bisaccia (Chieti, IT)
Abstract Slides Video
Presentation thumbnail
Invasive assessment of coronary microvascular function in sepsis: The COronary Microcirculation and Troponin Elevation in Severe Sepsis (COMTESS)-study
Doctor S. Lorstad (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Procedural complications during intracoronary acetylcholine provocation testing in patients with cardiac arrest
Doctor K. Tateishi (Chiba, JP)
Abstract Slides Video
Presentation thumbnail
Residual cholesterol:a non-predictive marker for major adverse cardiovascular events in patients with intermediate coronary lesions: a large-scale multicenter study
Doctor J. Ren (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Adherence to consensus recommendations in the care of patients with spontaneous coronary artery dissection from the ANZ-SCAD registry
Doctor Q. Dang (Hamilton, NZ)
Abstract Slides Video

Access the full session

Session thumbnail
Non-obstructive coronary disease: what's new in assessment and management
Video

The Event

Event poster

ESC Congress 2025

30 August 2025 09:05 CET
You may be interested in
thumbnail
Congress Session
Non-obstructive coronary disease: what's new in assessment and management
thumbnail
Congress Session
Microvascular dysfunction: optimising diagnosis and prognosis
thumbnail
Congress Session
Diagnosis and treatment of microvascular and epicardial coronary artery disease

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources